Amgen's Xgeva is still topping the recommendation list from NICE but this time, it has gained recommendation to serve certain groups of cancer patients, the ones, whose disease has unfortunately spread to their bones as well.

Above support got clear in the final draft guidance that was issued by the watchdog recommending its clear support to Xgeva (denosumab) for the treatment of people suffering from bone metastases from most solid cancer tumors.

The drug is powerful in its action in patients having bone metastases from breast cancer and also people suffering with bone metastases from solid tumors (other than breast or prostate), the suggestions cleared.

How does it work? Xgeva immediately helps in preventing the skeletal-related event's occurrences from cancer to serve benefits soon but yes, do not mistake to consider it as any anti-cancer or pain relief treatment, it is not that!

Amgen has earlier offered a confidential patient access scheme to help NHS lower the overall costs for the treatments and the new drug follows the same plan. Estimates have confirmed that a 120mg vial of denosumab costs around £309.86 and during the one year treatment, it needs 13 doses, which are priced at £4,028.18 after the discount. NICE agrees that the suggestions appraise a cost effective use of NHS resources.